Tiacumicin B Polymorphs Stabilization via XRPD Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical industry faces challenges in predicting and stabilizing polymorphs of drugs like Tiacumicin B, which affects their bioavailability and stability due to variations in crystal lattice and solvation states, making it difficult to ensure consistent absorption and dissolution rates.
Innovation Solution
The development of new polymorphs and solid states of Tiacumicin B, specifically crystal solvates with solvents such as propanol, acetic acid, chlorobenzene, and methyl-ethyl-ketone, which are characterized by distinct XRPD patterns and are suitable for storage, enhancing stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If different polymorphs of Tiacumicin B are used, then solubility and dissolution rate may improve, but predictability and stability of the crystalline form deteriorate
Solution Approach 1:
The patent applies preliminary action by pre-characterizing multiple polymorphs and solvates of Tiacumicin B with their specific XRPD patterns, stability profiles, and solubility characteristics. This advance characterization allows selection of the most suitable crystalline form before formulation development, improving predictability of bioavailability while maintaining stability.
Solution Approach 2:
The patent employs parameter changes by systematically varying crystallization conditions (solvents, temperature, pH) to generate and characterize different polymorphs and solvates. This approach enables identification of specific parameter combinations that yield stable, high-solubility forms, making the polymorph selection process more predictable and controllable.
2Reliability
If metastable polymorphs are used to improve solubility, then dissolution rate increases, but long-term stability deteriorates
Solution Approach 1:
The patent applies preliminary action by conducting stability studies on multiple polymorphs and solvates under various storage conditions before selecting the final formulation. This advance stability assessment allows identification of polymorphs that maintain their crystalline structure over time, ensuring both dissolution performance and long-term stability.
Solution Approach 2:
The patent employs beforehand cushioning by incorporating stabilizing excipients and optimizing formulation conditions to protect metastable polymorphs from transitioning to less soluble forms during storage. This protective approach maintains the high dissolution rate of metastable forms while preventing degradation and ensuring long-term stability.
3Duration of action of stationary object
If crystal solvates are formed to improve stability, then storage suitability improves, but complexity of characterization increases
Solution Approach 1:
The patent employs intermediary techniques by using XRPD as a primary characterization tool with distinct patterns for each solvate type. These characteristic diffraction patterns serve as intermediaries that simplify identification and characterization of different solvates, making the process more straightforward despite the complexity of the crystalline structures involved.
Solution Approach 2:
The patent applies the principle of distinctive identification (analogous to color changes) by establishing unique XRPD fingerprint patterns for each crystal solvate of Tiacumicin B. These distinctive patterns enable easy differentiation and characterization of various solvates without requiring complex analytical procedures, thus simplifying the characterization process while ensuring accurate identification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These new polymorphs and solid states improve the stability and bioavailability of Tiacumicin B by maintaining consistent XRPD patterns and solvation states, ensuring reliable absorption and dissolution rates, and are suitable for long-term storage.
Implementation Method 1
The polymorphs have different physical and chemical properties; for example, they may have different melting points and solubilities and they also usually exist in different habits. These variations cause differences in the X-ray diffraction patterns of the polymorphs and this technique is one of the main methods of detecting the existence of polymorphs.
Implementation Method 2
These variations cause differences in the X-ray diffraction patterns of the polymorphs and this technique is one of the main methods of detecting the existence of polymorphs.
Implementation Method 3
Crystalline solids can exist in several subphases, such as polymorphs, solvates, hydrates, and cocrystals. Polymorphs are different crystalline forms (at different free energy states) of the same compound.
Implementation Method 4
a drug together with an organic solvent (to form a solvate) or water (to form a hydrate), or another crystalline solid (to form co-crystals)
Data Source
AI summary
The present invention relates to new polymorphs consisting in crystallines solvates of Tiacumicin B, the solvates being propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene and methyl-ethyl-ketone. The present invention also relates to a new amorphous form of Tiacumicin B.